Advances in Targeted Therapy of Lymphoma

Journal of International Translational Medicine

Ji-feng Feng¹ 

[1] Department of Medical Oncology, Jiangsu Cancer Hospital Affiliated to Nanjing Medical University, Nanjing, Jiangsu, 210009, China;

关键词: Lymphoma;    Targeted agents;    Antigen;    Signaling pathway;    Tumor microenvironment;   

DOI  :  10.11910/2227-6394.2015.03.04.12

来源: DOAJ

【 摘 要 】

Abstract Lymphoma is the most common hematologic malignancy, and its incidence increases year by year. It is estimated that there are over 80 000 new cases of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL) in 2015 and more than 20 000 deaths. In recent years, the 5-year survival rate of patients with lymphoma has been over 50% as molecular targeted agents come out, and combination of novel specific targeted agents and traditional cytotoxic drugs brings about a revolution in the treatment of cancers. This review mainly discussed the novel targeted agents in the treatment of lymphoma from the following three aspects, including receptors and antigens acting on cell surface, signaling pathways and proteins acting on cells as well as tumor micro-environment.

【 授权许可】

Unknown